גינקולוגיה

Strontium Ranelate Reduces Vertebral Fracture Risk in Postmenopausal Osteoporosis


By Adrian Burton, Special to DG News, LISBON, PORTUGAL — May 15, 2002 — A pan-European study strongly suggests that oral strontium ranelate is a safe treatment for women with vertebral osteoporosis and that it has a unique mechanism of action. The findings were reported at the International Osteoporosis Foundation’s World Congress on Osteoporosis. Osteoporosis occurs because bone formation is reduced while its breakdown increases. “If we tried to define the ideal osteoporotic drug, it would increase bone formation and decrease bone resorption,” said Pierre Meunier, Prof. of Medicine at the Edouard Herriot Hospital, Lyon, France. “We have drugs capable of doing one or the other, but if we could find one capable of doing both, that would be nice.” The results of this study show strontium ranelate may be such a drug. The dose-ranging STRATOS study had already confirmed that a daily dose of two g is optimal in increasing lumbar bone mineral density (BMD). Now, a three year, randomized, double blind, placebo-controlled phase III study performed in 12 European countries has shown that this dose is capable of drastically reducing the relative risk of new vertebral fractures. The 1649 study subjects were divided into two parallel groups of mean age 69.7 (7.3) years and lumbar BMD 0.73 (0.12). Of these, 87.5 percent had at least one vertebral fracture. Patients received either the above dose of strontium ranelate or a placebo. All received concurrent calcium and vitamin D supplements.

0 תגובות

השאירו תגובה

רוצה להצטרף לדיון?
תרגישו חופשי לתרום!

כתיבת תגובה

מידע נוסף לעיונך

כתבות בנושאים דומים

© ‫ e-Med
 כל הזכויות שמורות

 

התכנים המוצגים באתר זה מיועדים לאנשי צוות רפואי בלבד

אם כבר נרשמת, יש להקליד את פרטי הזיהוי שלך
עדיין לא נרשמת? באפשרותך לבצע רישום כאן
להרשמה לאתר